Boston Scientific Corporation's Anti-Stroke Watchman Heart Implant Lands A Date With The FDA

An FDA advisory panel is slated to meet next month to discuss whether to recommend approval for Boston Scientific's anti-stroke Watchman heart implant. Boston Scientific (NYSE:BSX) won a date with an FDA advisory panel for its Watchman heart implant after the anti-stroke device met 2 of 3 endpoints in a clinical trial. The Watchman implant, already available in 30 countries, is introduced via catheter and threaded into the heart to close off the left atrial appendage and capture any blood clots that may form there.

Help employers find you! Check out all the jobs and post your resume.